I don't see any mention of it on this board but there was a meeting on 9/22/2015 that FDA held to hear from HD community about how they felt about Huntington's disease. The meeting ended with a commentary by Eric Bastings saying that no drugs are being held up for safety. In fact, there are two including OMS-824. Comments are being taken up until November 23 2015 if there are any here who have relatives with HD or wish to comment. You can listen to the webcast here as well as a link to the docket comments: wwwDOTfdaDOTgov/Drugs/NewsEvents/ucm451807DOThtm
Sentiment: Strong Buy
I would be delighted with $14 million....but that's a LOT to ask. We had $3.2 million in revenue last quarter ($3.1 million from Omidria). $14 million would be a ~330% increase quarter-over-quarter. That's spectacular!! If we can get to ~$8 million, that's a ~150% increase quarter-over-quarter. Heck, $14 million by December would be great!! GLTA
I checked on Linked In. They seem to have very experienced Marketing and sales time with great experience in biotech and pharma Field. We should see great result eventually.
With sales people in phoenix,boston, miami,austin, houston newyork,minnesota, cleveland,fresno,st louis,detroit,grand rapids, jacksonville,georgia, new jersey, north carolina, orlando, louisianna,tennesee, our numbers on omidria should be ready to sky rocket. Check linkedin and you can see all 135 employees for Omeros and see the backgrounds of everyone, If not this quarter next two for sure
6M....and I really hope I am wrong. This will be more about 721 than anything IMO.
taking two words from the SA article regarding dilution over a month ago. "Any day" we will hear about 721, 824, EU partner and 103 milestone payment.
Six professional analysts say $7.2 million for Q3 revenues. I'll go with that. Anything better will be terrific. IMO those calling for $12M-$14M are shorts trying to boost expectations so that if revenues come in at $7M-$8M they can moan and groan.
Any words on OMS 721, OMS 824 restart and an EU Omidria partner will be welcome too.
If they will hit 14MM in sales then short covering will put it back around $20 for sure.
8-9 mil. Yahoo analyst estimates were updated the sales numbers dropped due to a new analyst posting their numbers.
The board is as quiet as the company, OMS 721 update would be great if the endpoints keep looking good , lots of possibilities for huge upside
Also going to guess the company has selected the medium dosage. Same as the drug on fda hold which wa on the medium dosage. The rat(s) that had the issue was on high dosage
Going to say high dosage completed and we will get the data for the remaining two high dosage patients and maybe up to 5 patients that have completed and have some data available for the earnings PR. So I think we will get an update on 7 patients.
The momo traders may be coming in based on the last oms721 pop. Why not buy at these levels for a chance at 20-30 range?
Johnny...Go to my links date 8/25/2015 I spelled it all out , to long to due again, but it is there. LETS GO OMER! (have forget the Mets now ,but I still love them).
yes, dmoke you nailed it last qtr, but not sure what your basing the 14mil for this qtr, but i hope your right.
Hey Johnny. Remember me ,I,m the one who call $3mm for the second Qt. hit it on the head, and back in Aug. i made the call for third Qt. ARE YOU READY! $14MM I,m still standing by it ... Good Luck To All! What a great time to buy.
Sentiment: Strong Buy